Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years

Rheumatology

Volumn 51, Issue 4, 2012, Pages 759-761

  Gullick, Nicola J ^a   Oakley, Stephen P ^a   Zain, Amir ^a   Gibson, Terence ^a   Jones, Tim ^a   Mistlin, Alan ^a   Rees, Jonathan D ^a   Panayi, Gabriel S ^a   Kirkham, Bruce W ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; CLINICAL PRACTICE; COMORBIDITY; DIABETES MELLITUS; DISEASE DURATION; FUNCTIONAL STATUS; GOAL DIRECTED THERAPY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HYPERTENSION; LETTER; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SHORT COURSE THERAPY; THERAPY; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GOALS; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858665712     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker399     Document Type: Letter

References (10)

1. Smolen JS, Aletaha D, Bijlsma JWJ et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
2. Puolakka K, Kautiainen H, Möttönen T et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005;52:36-41.
3. Korpela M, Laasonen L, Hannonen P et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004;50:2072-81.
4. Smolen JS, Han C, van der Heijde DMFM et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade. Ann Rheum Dis 2009;68:823-7.
5. Landewe R, Van der Heijde D, Klareskog L et al. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119-25.
6. Schoels M, Knevel R, Aletaha D et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010;69:638-43.
7. Hewlett SA. Patients and clinicians have different perspectives on outcomes in arthritis. J Rheumatol 2003;30: 877-9.
8. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
9. Aletaha D, Strand V, Smolen JS, Ward MM. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 2008;67:238-43.
10. Heiberg T, Kvien TK, Mowinckel P et al. Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:967-71.